MDL 63042

Drug Profile

MDL 63042

Alternative Names: A-40,926

Latest Information Update: 06 Feb 2017

Price : $50

At a glance

  • Originator Biosearch Italia
  • Class Antibacterials; Glycopeptides
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 06 Feb 2017 Discontinued - Preclinical for Bacterial infections in Italy (unspecified route)
  • 30 Sep 2005 Vicuron Pharmaceuticals has since been acquired by and merged into Pfizer
  • 14 Jul 1998 No-Development-Reported for Bacterial infections in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top